Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates
Por:
Sepulveda, M, Aldea, M, Escudero, D, Llufriu, S, Arrambide, G, Otero-Romero, S, Sastre-Garriga, J, Romero-Pinel, L, Martinez-Yelamos, S, Sola-Valls, N, Armangue, T, Sotoca, J, Escartin, A, Robles-Cedeno, R, Ramio-Torrent, L, Presas-Rodriguez, S, Ramo-Tello, C, Munteis, E, Pelayo, R, Gubieras, L, Brieva, L, Ortiz, N, Hervas, M, Mane-Martinez, MA, Cano, A, Vela, E, Tintore, M, Blanco, Y, Montalban, X, Graus, F, Saiz, A
Publicada:
1 dic 2018
Resumen:
Background: Population-based studies on neuromyelitis optica spectrum disorders (NMOSD) are limited, and it is unclear whether the rates have changed with the implementation of the new 2015 criteria. Objectives: To estimate the incidence and prevalence of NMOSD in Catalonia (Spain), using both the 2006 and the 2015 criteria. Methods: In this clinic-based retrospective study, patients diagnosed with NMOSD between 2006 and 2015 were identified using multiple sources, including direct contact to all Catalan hospitals, identification of cases through the Catalan Health Surveillance System, and registry of antibodies to aquaporin-4 (AQP4-IgG) and myelin oligodendrocyte glycoprotein (MOG-IgG) in a reference laboratory. The incidence rate was calculated for the period 1 January 2006-1 January 2016 and prevalence for the date 1 January 2016. Results: We identified 74 patients (by the 2015 criteria). Most patients were Caucasian (81%), and female (76%) with a median age at disease onset of 42 years (range, 10-76 years). In total, 54 (73%) patients were positive for AQP4-IgG, 11 (15%) double-seronegative, and 9 (12%) MOG-IgG-positive. Rates of incidence and prevalence (0.63/1,000,000 person-years and 0.89/100,000, respectively) were 1.5-fold higher than those reported by the 2006 criteria. Lowest rates were seen in children and elder people and highest in women and middle-aged people (40-59 years). The female predominance was lost in incident AQP4-IgG-seronegative children and AQP4-IgG-positive elder people. MOG-IgG and double-seronegativity contributed similarly but did not influence the long-term outcome. Conclusion: The new criteria increase the estimates, but NMOSD remains as a rare disease. The differences in age- and sex-specific estimates highlight the importance of the serologic classification.
Filiaciones:
Sepulveda, M:
Univ Barcelona, Hosp Clin Barcelona, Lab Adv Imaging Neuroimmunol Dis, Ctr Neuroimmunol, Villarroel 170, E-08036 Barcelona, Spain
Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAP, Villarroel 170, E-08036 Barcelona, Spain
Aldea, M:
Univ Barcelona, Hosp Clin Barcelona, Dept Prevent Med & Epidemiol, Barcelona, Spain
Escudero, D:
Univ Barcelona, Hosp Clin Barcelona, Lab Adv Imaging Neuroimmunol Dis, Ctr Neuroimmunol, Villarroel 170, E-08036 Barcelona, Spain
Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAP, Villarroel 170, E-08036 Barcelona, Spain
Llufriu, S:
Univ Barcelona, Hosp Clin Barcelona, Lab Adv Imaging Neuroimmunol Dis, Ctr Neuroimmunol, Villarroel 170, E-08036 Barcelona, Spain
Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAP, Villarroel 170, E-08036 Barcelona, Spain
Arrambide, G:
Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Vall dHebron Inst Recerca, Serv Neurol Neuroimmunol,Ctr Esclerosi Multiple C, Barcelona, Spain
Otero-Romero, S:
Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Vall dHebron Inst Recerca, Serv Neurol Neuroimmunol,Ctr Esclerosi Multiple C, Barcelona, Spain
Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Dept Prevent Med & Epidemiol, Barcelona, Spain
Sastre-Garriga, J:
Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Vall dHebron Inst Recerca, Serv Neurol Neuroimmunol,Ctr Esclerosi Multiple C, Barcelona, Spain
Romero-Pinel, L:
Hosp Univ Bellvitge, Dept Neurol, Multiple Sclerosis Unit, Barcelona, Spain
Martinez-Yelamos, S:
Hosp Univ Bellvitge, Dept Neurol, Multiple Sclerosis Unit, Barcelona, Spain
Sola-Valls, N:
Univ Barcelona, Hosp Clin Barcelona, Lab Adv Imaging Neuroimmunol Dis, Ctr Neuroimmunol, Villarroel 170, E-08036 Barcelona, Spain
Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAP, Villarroel 170, E-08036 Barcelona, Spain
Armangue, T:
Univ Barcelona, Hosp Clin Barcelona, Lab Adv Imaging Neuroimmunol Dis, Ctr Neuroimmunol, Villarroel 170, E-08036 Barcelona, Spain
Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAP, Villarroel 170, E-08036 Barcelona, Spain
Univ Barcelona, Hosp St Joan Deu Barcelona, Pediat Neuroimmunol & Neuroinfect Unit, Barcelona, Spain
Ctr Biomed Network Res Rare Dis CIBERER, Madrid, Spain
Sotoca, J:
Hosp Santa Creu & Sant Pau, Dept Neurol, Barcelona, Spain
Escartin, A:
Hosp Santa Creu & Sant Pau, Dept Neurol, Barcelona, Spain
Robles-Cedeno, R:
Doctor Josep Trueta Univ Hosp, Neurol Dept, Neuroimmunol & Multiple Sclerosis Unit, Girona, Spain
Biomed Res Inst IDIBGI, Girona, Spain
Univ Girona, Med Sci Dept, Girona, Spain
Ramio-Torrent, L:
Doctor Josep Trueta Univ Hosp, Neurol Dept, Neuroimmunol & Multiple Sclerosis Unit, Girona, Spain
Biomed Res Inst IDIBGI, Girona, Spain
Univ Girona, Med Sci Dept, Girona, Spain
Presas-Rodriguez, S:
Hosp Badalona Germans Trias & Pujol, Neurosci Dept, Multiple Sclerosis Unit, Barcelona, Spain
Ramo-Tello, C:
Hosp Badalona Germans Trias & Pujol, Neurosci Dept, Multiple Sclerosis Unit, Barcelona, Spain
Munteis, E:
Parc Salut Mar, Multiple Sclerosis Unit, Neurol Dept, Barcelona, Spain
Pelayo, R:
Inst Guttmann, Barcelona, Spain
Gubieras, L:
Hosp St Joan Despi Moises Broggi, Neurol Dept, Multiple Sclerosis Unit, Barcelona, Spain
Brieva, L:
Hosp Arnau Vilanova, Neurol Dept, Multiple Sclerosis Unit, Lleida, Spain
Ortiz, N:
Hosp Univ St de Joan Reus, Neurol Dept, Tarragona, Spain
Hervas, M:
Hosp Parc Tauli de Sabadell, Neurol Dept, Multiple Sclerosis Unit, Barcelona, Spain
Mane-Martinez, MA:
Hosp Univ Tarragona Joan XXIII, Neurol Dept, Tarragona, Spain
Cano, A:
Hosp Mataro, Neurol Dept, Barcelona, Spain
Vela, E:
Catalan Hlth Serv, Unit Informat & Knowledge, Barcelona, Spain
Tintore, M:
Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Vall dHebron Inst Recerca, Serv Neurol Neuroimmunol,Ctr Esclerosi Multiple C, Barcelona, Spain
Blanco, Y:
Univ Barcelona, Hosp Clin Barcelona, Lab Adv Imaging Neuroimmunol Dis, Ctr Neuroimmunol, Villarroel 170, E-08036 Barcelona, Spain
Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAP, Villarroel 170, E-08036 Barcelona, Spain
Montalban, X:
Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Vall dHebron Inst Recerca, Serv Neurol Neuroimmunol,Ctr Esclerosi Multiple C, Barcelona, Spain
Univ Toronto, St Michaels Hosp, Div Neurol, Toronto, ON, Canada
Graus, F:
Univ Barcelona, Hosp Clin Barcelona, Lab Adv Imaging Neuroimmunol Dis, Ctr Neuroimmunol, Villarroel 170, E-08036 Barcelona, Spain
Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAP, Villarroel 170, E-08036 Barcelona, Spain
Saiz, A:
Univ Barcelona, Hosp Clin Barcelona, Lab Adv Imaging Neuroimmunol Dis, Ctr Neuroimmunol, Villarroel 170, E-08036 Barcelona, Spain
Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAP, Villarroel 170, E-08036 Barcelona, Spain
Green Accepted
|